NCT00219128View on ClinicalTrials.gov

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.

PHASE3CompletedINTERVENTIONAL
Enrollment

671

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Hypertension
Interventions
DRUG

aliskiren

Trial Locations (1)

07936

Novartis Pharmaceuticals, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY